Literature DB >> 18341641

Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.

Emmanuelle Boulanger, Véronique Meignin, Eric Oksenhendler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18341641     DOI： 10.1111/j.1365-2141.2008.07057.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Authors:  Jason P Wong; Timothy J Stuhlmiller; Louise C Giffin; Carolina Lin; Rachele Bigi; Jichen Zhao; Weihe Zhang; Ariana G Bravo Cruz; Steven I Park; H Shelton Earp; Dirk P Dittmer; Stephen V Frye; Xiaodong Wang; Gary L Johnson; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

Review 3.  Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.

Authors:  Erin G Reid
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

4.  Update on HHV-8-Associated Malignancies.

Authors:  Meena Sunil; Erin Reid; Mary Jo Lechowicz
Journal:  Curr Infect Dis Rep       Date:  2010-03-26       Impact factor: 3.725

5.  New targets of PS-341: BAFF and APRIL.

Authors:  Wuping Li; Juan Li; Chang Su; Wai Yi Zou; Shaokai Luo
Journal:  Med Oncol       Date:  2009-05-19       Impact factor: 3.064

6.  Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model.

Authors:  Yoshioki Shiraishi; Kumiko Gotoh; Tomomi Towata; Tatsuya Shimasaki; Shinya Suzu; Akihiro Kojima; Seiji Okada
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

7.  Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature.

Authors:  A Antar; H El Hajj; M Jabbour; I Khalifeh; F El-Merhi; R Mahfouz; A Bazarbachi
Journal:  Blood Cancer J       Date:  2014-03-07       Impact factor: 11.037

8.  NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.

Authors:  David J Hughes; Jennifer J Wood; Brian R Jackson; Belinda Baquero-Pérez; Adrian Whitehouse
Journal:  PLoS Pathog       Date:  2015-03-20       Impact factor: 6.823
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.